#NewAseBioMember | “AseBio is leader in grouping and promoting the biotechnology sector and biotech companies in Spain”
Meet Biointaxis, our new member. We spoke with Antoni Matilla Dueñas CEO, Co-fundador.
AseBio. What does your company's work bring to the table and what is its strength?
Antoni Matilla Dueñas. Biointaxis is a spin-off company established in 2018 from the Germans Trias i Pujol Research Institute (IGTP) in Badalona (Barcelona) with the aim of developing advanced gene therapies to treat rare neurological diseases. The first product to be developed aims to cure Friedreich's ataxia, a neurodegenerative disease with severe neurological and cardiac defects. Biointaxis scientists are a reference in research into rare diseases and in particular ataxias, making Biointaxis a reference in the development of advanced therapies for this type of diseases.
AseBio. What is AseBio for you?
Antoni Matilla Dueñas. AseBio is leader in grouping and promoting the biotechnology sector and biotech companies in Spain, collaborating with national and international public and private organizations in the sector.
AseBio. When did you first hear about AseBio?
Antoni Matilla Dueñas. From the first moment Biointaxis was established in 2018 through colleagues, companies and organizations, both from the public and private sectors.
AseBio. What do you expect from being part of an association like AseBio?
Antoni Matilla Dueñas. Firstly, give visibility to Biointaxis to position it as a leader in the development of advanced gene therapies for rare diseases. On the other hand, to establish AseBio as a reference framework to establish strategic collaborations with both public and private sectors.
AseBio. What is the biggest challenge facing the biotech sector or your company?
Antoni Matilla Dueñas. In my opinion, the biggest challenge is to increase the size of both the sector and at the individual level of Biointaxis, with growth with a significant contribution of income. I believe that the sector is currently consolidated with the support of public and private agents and the challenge for all actors in the sector is growth in size, turnover and investment.